SHTDY SINOPHARM GROUP CO
- 13.388
- +0.056+0.42%
SINOPHARM GROUP CO News
Analysts Offer Insights on Healthcare Companies: BioLife Solutions (BLFS) and Sinopharm Group Co (OtherSHTDF)
Sinopharm Holdings (1099.HK): Profits are still under pressure in the short term and expect continued improvement in 2025
Sinopharm Holdings (1099.HK): The device sector is under pressure and expects steady operation for 25 years
HK stocks anomaly | Sinopharm (01099) fell by nearly 4% during the day, performance in the first three quarters fell short of expectations, institutions lowered the company's target price.
Dah Sing: Recommends to shareholding sinopharm (01099) with a target price lowered to HK$24.
Sinopharm Group Target Price Cut to HK$28.46 From HK$30.33 by Nomura >1099.HK
Nomura: lowers sinopharm (01099) target price to 28.46 Hong Kong dollars, maintains a "buy" rating
Bocom Intl: rates the Mainland pharmaceutical industry as "leading", focusing on innovative and consumer-driven targets.
Sinopharm Holdings (1099.HK): Segment management differentiation is optimistic about H2 month-on-month improvement
Citigroup: Buy rating on Sinopharm (01099) with target price lowered to 26 Hong Kong dollars
HKEx: Sinopharm (01099) continued to fall 4%, with revenue and net profit declining in the first half of the year. Institutions have lowered their earnings forecasts and target prices for the company.
Sinopharm Holdings (01099.HK): 1H24 results are in line with expectations, financial expenses declined year-on-year
Nomura Adjusts Sinopharm's Price Target to HK$30.33 From HK$32.39, Keeps at Buy
Nomura: Maintains a "buy" rating on Sinopharm (01099), with a lowered target price of HKD 30.33.
Sinopharm Holdings (01099.HK): Main business maintains growth trend, transformation and innovation continue to advance
Damo: Target price for Sinopharm Holdings (01099) “increase in holdings” rating reduced to HK$28
Sinopharm Holdings (1099.HK): Shareholders' equity increased 6.2% year-on-year in '23, gross margin is still declining
Sinopharm Holdings (1099.HK): 2023 results slightly lower than expected; high dividend rate expected to continue
Sinopharm Holdings (1099.HK): Expense Control Continues to Deepen and Expect Steady Growth in Performance
Sinopharm Holdings (01099.HK): Performance is in line with expectations, and the cost rate is further optimized
No Data